EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug Discovery in the Age of Artificial Intelligence: Transformative Target-Based Approaches

Akshata Yashwant Patne iD, Sai Madhav Dhulipala, William Lawless, Satya Prakash, Shyam S Mohapatra iD, Subhra Mohapatra iD

International Journal of Molecular Sciences · 14.11.2024 · 25 (22) · 12233

DOI: 10.3390/ijms252212233 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.11.2024. Verfasst von Akshata Yashwant Patne und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research and Education in Nanobioengineering, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, T…. Hauptthemen laut MEDLINE: Drug Discovery, Neural Networks, Computer. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, US Dept. of Veterans Affairs Research Career Scientist (RCS), Veterans Affairs Merit Review.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complexities inherent in drug development are multi-faceted and often hamper accuracy, speed and efficiency, thereby limiting success. This review explores how recent developments in machine learning (ML) are significantly impacting target-based drug discovery, particularly in small-molecule approaches. The Simplified Molecular Input Line Entry System (SMILES), which translates a chemical compound’s three-dimensional structure into a string of symbols, is now widely used in drug design, mining, and repurposing. Utilizing ML and natural language processing techniques, SMILES has revolutionized lead identification, high-throughput screening and virtual screening. ML models enhance the accuracy of predicting binding affinity and selectivity, reducing the need for extensive experimental screening. Additionally, deep learning, with its strengths in analyzing spatial and sequential data through convolutional neural networks (CNNs) and recurrent neural networks (RNNs), shows promise for virtual screening, target identification, and de novo drug design. Fragment-based approaches also benefit from ML algorithms and techniques like generative adversarial networks (GANs), which predict fragment properties and binding affinities, aiding in hit selection and design optimization. Structure-based drug design, which relies on high-resolution protein structures, leverages ML models for accurate predictions of binding interactions. While challenges such as interpretability and data quality remain, ML’s transformative impact accelerates target-based drug discovery, increasing efficiency and innovation. Its potential to deliver new and improved treatments for various diseases is significant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryNeural Networks, ComputerHumansArtificial IntelligenceDrug DesignMachine LearningDeep LearningAlgorithms

Stichwörter der Autor:innen

drug discoverygeneral adversarial networksgraph neural networksphenotypic approachesrandom foreststarget-based approaches

Autor:innen und Institutionen

  • Center for Research and Education in Nanobioengineering, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
  • Taneja College of Pharmacy Graduate Programs, MDC30, 12908 USF Health Drive, Tampa, FL 33612, USA.
  • Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
  • Research Service, James A. Haley Veterans Hospital, Tampa, FL 33612, USA.
  • Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine and Health Sciences, McGill University, 3775 University Street, Montreal, QC H3A 2B4, Canada.

ORCID-Profile: Akshata Yashwant Patne, Shyam S Mohapatra, Subhra Mohapatra

Förderung

  • BLRD VA
  • US Dept. of Veterans Affairs Research Career Scientist (RCS)
  • Veterans Affairs Merit Review
  • Public Service Grant RO1

Zitieren

APA

Patne, A. Y., Dhulipala, S. M., Lawless, W., Prakash, S., Mohapatra, S. S., & Mohapatra, S. (2024). Drug Discovery in the Age of Artificial Intelligence: Transformative Target-Based Approaches. International Journal of Molecular Sciences, 25(22), 12233. https://doi.org/10.3390/ijms252212233

Vancouver

Patne AY, Dhulipala SM, Lawless W, Prakash S, Mohapatra SS, Mohapatra S. Drug Discovery in the Age of Artificial Intelligence: Transformative Target-Based Approaches. International Journal of Molecular Sciences. 2024;25(22):12233. doi:10.3390/ijms252212233

BibTeX
@article{Patne2024,
  author = {Patne, Akshata Yashwant and Dhulipala, Sai Madhav and Lawless, William and Prakash, Satya and Mohapatra, Shyam S and Mohapatra, Subhra},
  title = {Drug Discovery in the Age of Artificial Intelligence: Transformative Target-Based Approaches},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {22},
  pages = {12233},
  doi = {10.3390/ijms252212233}
}
Kostenlos starten →